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Abstract
Conventional liposome preparation methods bear many limitations, such as poor entrap-
ment efficiencies for hydrophilic drugs, batch size limitations, and limited options for 
aseptic manufacturing. Liposome preparation by dual centrifugation (DC) is able to 
overcome most of these limitations. DC differs from normal centrifugation by an addi-
tional rotation of the samples during the centrifugation process. Thus, the direction of the 
centrifugal forces changes continuously in the sample vials. The consequential powerful 
sample movements inside the vials result in powerful homogenization of the sample. Since 
this “in-vial” homogenization is optimal for viscous samples, semisolid “vesicular phos-
pholipid gels” (VPGs) are preferred intermediates in the liposome manufacturing by DC. 
The DC method easily enables aseptic preparation and is gentler as compared to other 
methods, such as high-pressure homogenization. The method allows very small samples 
to be prepared, and VPG batches down to 1–5 mg scale have been prepared successfully. 
VPGs have several applications; they are attractive as depot formulations, or as stable stor-
age intermediates, and can be easily transferred into conventional liposomal formulations 
by simple dilution. Here, we aim to present the novel DC-liposome technique; the con-
cept, advantages, and limitations; and provide an overview of the experiences of liposome 
preparation by DC so far.
Keywords: dual centrifugation, dual asymmetric centrifugation, liposomes, vesicular 
phospholipid gels, homogenization, aseptic manufacturing
1. Introduction
Liposomes as a drug delivery system are considered to be one of the most successful devel-
opments regarding the transfer from laboratory research to actual products on the market. 
© 2017 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
From the first liposome drug delivery system approved for human use by the Food and 
Drug Administration (FDA) in 1995 (Doxil®), the field has expanded and, currently, 15 lipo-
some- or lipid-based drug formulations are approved for human use [1]. Moreover, in 2013, 
there were 589 interventional drug studies focusing on liposomal drug formulations, of 
which at least 107 were active (ClinicalTrials.gov). The development in the field of liposome 
technology for extensive clinical studies requires industrial scale production not only due 
to the larger quantities but also under quality assurance and Good Manufacturing Practice 
guidelines [2].
The aim of this chapter is to provide an overview over the state-of-the-art of a novel liposome 
preparation technique: “in-vial” homogenization using dual centrifugation (DC). First, we 
explain the concept of the new method and why highly concentrated lipid dispersions, usually 
named vesicular phospholipid gels (VPGs), offer several advantages to this method. Second, 
we comment on the potential of this method and on our own experiences when applying DC 
for the preparation of VPGs or liposome dispersions. Finally, we compare the two dual cen-
trifuges that have been used for liposome production so far: the Speedmixer DAC 150 FVZ 
(Hauschild GmbH & Co KG, Hamm, Germany), used in the first liposome manufacturing by 
this technique, as well as the recently constructed ZentriMix 380 R (Andreas Hettich GmbH 
& Co KG, Tuttlingen, Germany).
2. Liposome preparation by dual centrifugation: concept and mode of 
action
One of the most important and easy ways to prepare liposomes is to homogenize mem-
brane-forming lipids together with an aqueous phase like a buffer and the drug substance 
to be entrapped. As homogenization tools, high-pressure homogenizers [3, 4], the “French 
press” [5, 6], microfluidizers [7, 8], and related devices can be used. For entrapping water-
soluble drugs into liposomal vesicles with the highest possible entrapping efficiency (EE), 
it is of advantage to homogenize highly concentrated lipid-water-drug mixtures. Since this 
is also the preferred way to make liposomes by DC, the characteristics of this strategy will 
be discussed first, followed by the presentation of the concept of DC and its use to make 
liposomes.
2.1. Background: preparation of liposomes from highly concentrated lipid-water mixtures 
by homogenization
Homogenization of membrane-forming lipids together with an amount of water that is only 
sufficient to hydrate the polar head groups of the lipids (typically 50–70% water) results in 
highly concentrated, vesicular phospholipid gels (VPG) [3, 9]. Since the water used for VPG 
production is not sufficient to fill the inner core of the liposomes, it can be suggested that VPGs 
does not contain vesicular liposomes, but preliposomes that are expected to be flat structures 
without an aqueous core (Figure 1). The amount of water, which is sufficient only to hydrate 
the polar head groups, depends on the lipids used for VPG production. If bulky water-binding 
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structures like PEG-chains are part of the lipid membranes, more water is needed in contrast 
to lipids carrying only phosphocholine head groups [10].
VPGs have a creamy consistency [11] and can directly be used as depot formulations, e.g., as 
subcutaneous injectable depots [12, 13] or can be dispersed in an excess of water to get normal 
aqueous liposomal formulations [14]. Dispersion of the VPGs allows the formation of nor-
mal liposomes by filling the preliposomes with additional water molecules, which can easily 
diffuse across the lipid membranes (Figure 2). Since in preliposomes the water molecules 
together with the water-soluble drug molecules were only distributed over the surfaces of 
the polar membranes, and since the surface area inside the liposomes is nearly as large as 
outside, it becomes clear that EE values up to 50% can be reached in the dispersed liposomal 
formulations [10, 15–17].
Figure 1. Schematic view of a VPG consisting of preliposomes without an aqueous core. Roughly, all water molecules—
together with water-soluble drug compounds—are in use for hydrating the polar head groups of the membrane forming 
lipids.
Figure 2. Schematic drawing of preliposomes in a VPG made by homogenization of a highly concentrated lipid-water 
mixture. The amount of water is sufficient to hydrate the phospholipid head groups, but is not sufficient to form 
vesicular, water-filled liposomes. The flat preliposomes became vesicular after dispersion of the preliposomes in an 
excess of water.
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However, EE values higher than 50% for VPG-derived liposomes have been reported. This 
“overload” of water-soluble drugs is most probably due to the formation of multilamellar 
preliposomes and—after dispersion—of multilamellar liposomes (MLVs) (Figure 2). In MLVs, 
more of the membrane-associated, water-soluble drug molecules are entrapped due to the 
“entrapment” of additional membranes. Unfortunately, only a few articles reporting EE val-
ues >50% present also data on lamellarity—e.g., EM pictures [10, 17] or NMR studies.
Liposomes made by homogenization via VPG intermediates tend to have a higher lamellarity 
as seen by EM pictures [10, 17]. The lamellarity can somewhat be influenced by the type of lip-
ids used [10]. Using lipids that ease the interactions between the surfaces of two membranes 
like PEG-carrying phospholipids leads to a higher lamellarity [17], whereby this interaction 
is further supported by the close vicinity of the membranes due to the low amount of water 
in the VPGs. In addition, also compounds to be entrapped may have an influence. Especially 
charged or very polar compounds that help to enable membrane-surface interactions like the 
multivalent-charged DNA molecules or divalent cations result preferably in the formation of 
MLVs during VPG production [16], and thus in very high EE-values.
In summary, the formation of liposomes with high EE values for water-soluble drug mol-
ecules as well as the formation of MLVs depends largely on the high lipid/water ratio used. 
Using an excess of water, EE as well as lamellarity goes down. Vice versa, using only the mini-
mal necessary amount of water, EE is at its maximum, but lamellarity will be high as well.
Theoretically, reduction of the liposome diameter might help to reduce lamellarity, simply 
because in small liposomes there is only limited space to accommodate additional membranes. 
However, the average sizes of liposomes made by homogenization of highly concentrated lipid 
mixtures are small, but seldom below 100 nm with PI values > 0.2 (PCS (Photon Correlation 
Spectroscopy), intensity weighted1) [10, 16–21]. At a first glance, this appears somewhat confus-
ing, since it is known that the liposome diameters clearly depend on the energy by which the 
highly concentrated lipid-water mixture has been treated and thus, liposomes made by HPH 
would have been expected to be very small.
The limited possibility of making very small liposomes via a VPG intermediate can be dis-
cussed as an intrinsic property of its high lipid concentration, typically >40% (w/v). During 
homogenization, the bigger membrane vesicles, which resulted from the initial hydration of 
the lipids, are broken into smaller membrane fragments, which spontaneously form smaller 
vesicles by self-organization. These smaller vesicles are disrupted again, forming even smaller 
vesicles. However, below a certain size, these lipid fragments not only form smaller vesicles 
by self-organization but also start to recombine into bigger vesicles. This process of recombi-
nation is more probable at an immediate vicinity of these fragments—or, in other words—at 
higher lipid concentrations as used for VPG-preparation.
To sum up, homogenization of highly concentrated lipid blends has been the preferred way 
to make liposomes with high EE for water-soluble drugs. The liposome sizes are still small 
enough even for parenteral use as well as for tumor accumulation via the so-called enhanced 
1Many articles about liposomes made by HPH or DC present number-weighted PCS results, which values are much 
lower than the respective intensity-weighted PCS values.
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permeability and retention effect (EPR-effect) [22]. The rather high content of multilamellar 
liposomes contributes to reach EE values of >50%. It has to be mentioned that multilamellar-
ity of liposomes has never been reported as a problem in preclinical studies, e.g., in mice [14]. 
Furthermore, a high lipid load is sometimes of advantage. It has been found that liposomes 
made from hydrogenated phospholipids (PL) have anti-metastatic properties [23, 24] and that 
this effect is due to the high load of hydrogenated PL [25].
Despite the above-described advantages of liposomes made by homogenization, the homog-
enization tools currently in use have its limitations, especially for making liposomes in small 
batch sizes, under gentle and aseptic conditions. There is, therefore, a need for an alternative 
method that might overcome these limitations, which are listed below:
2.1.1. Batch sizes
Most of the homogenizers that are in use for liposome preparation have been developed to pro-
cess bigger batches or at least batch sizes of several grams and very small batches are not pos-
sible due to the relatively high dead volumes of the devices. These “high” minimum batch sizes 
are a problem when only small amounts of liposomes are needed, i.e., for cell culture or animal 
experiments, and especially when the raw material applied is expensive or rare, like siDNA.
2.1.2. Harsh conditions
Since the samples in the normal homogenizers are in direct contact with the homogenizing 
unit (e.g., the homogenizing valve in HPH) for only a very short period of time (milliseconds), 
a large quantity of energy is needed to successfully homogenize the sample in that moment 
(VPG production with HPH: typically >700 bar, 10 cycles). Thus, the samples will heat up, 
which might damage the samples.
2.1.3. Cleaning/metal contamination
During homogenization, the liposomes are in contact with various parts of the homogenizers. 
Thus, a careful device cleaning prior to the liposome preparation is necessary. Furthermore, 
since the liposomes are squeezed through pumps and valves during homogenization, there is 
always the danger of product contamination with metal abrasion.
2.1.4. Number of samples
None of the known homogenizers is able to process more than one sample at once, which 
makes screening approaches burdensome, e.g., the screening for an optimal lipid composition 
for a new liposomal formulation.
2.1.5. Sterile formulations
The dimensions of the known homogenizers are rather big, only a few of them can be placed 
into a sterile bench. Thus, the production of sterile liposome formulations that are needed for 
cell culture, animal experiments, or for human use is difficult.
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The above-listed limitations can be overcome by using dual centrifugation (DC) as a homog-
enization technique [15]. DC easily allows the gentle preparation of liposomes and other lipid 
nanoparticles in very small batch sizes. The use of closed and disposable vials avoids metal 
contamination as well as cleaning of the homogenization device (“in-vial” homogenization). 
Using sterile vials allows production of sterile formulations. Furthermor, since the vials are 
tihgtly closed during DC, safe handling of particles with toxic compounds is possible. Many 
samples can be produced in parallel, which allows effective formulation screening.
2.2. Principles of dual centrifugation (DC)
DC is based on centrifugation. But in contrast to normal centrifugation where samples are 
turned around a central axis, during DC, the sample vials are additionally turned around a 
second rotation axis (Figure 3). Due to that the direction of high centrifugal acceleration in the 
sample vials changes continuously, which result in high frequent and very powerful sample 
movements. In contrast to normal centrifugation, DC is not a separation technique. DC is sim-
ply the opposite, a process which can be used for extremely powerful sample mixing, milling, 
extraction, dissolution, and homogenization, which is the central theme of this chapter.
While using DC for mixing purposes is well known for decades (e.g., for the mixing of two-
component dental filling materials), its usefulness for homogenization and for the prepara-
tion of lipid nanoparticles was first described in 2008 [15]. Homogenization power of a DC 
depends on the rotating speed and the diameter of the dual rotor (→ centrifugal acceleration) 
as well as the rotating speed around the second axis (→ frequency of changing the direction 
of centrifugal acceleration in the sample vial). Furthermore, the shape and the orientation 
of the sample vial placed in the dual rotor strongly influence the homogenization power. 
Figure 3. Principles of dual centrifugation (DC). Left: Dual rotor with a vial turning around its own axis (only one vial is 
shown). Right: Visualization of the changing direction of the centrifugal forces in a sample vial.
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Homogenization power can also be increased by adding homogenization aids to the samples 
like ceramic beads.
2.2.1. Speed of main and secondary rotation
These parameters strictly depend on the type of dual centrifuge used for liposome prepara-
tion. Until now, two different dual centrifuges have been successfully used for this purpose, 
the ZentriMix 380R and the Speedmixer DAC 150. Despite being different in many aspects 
(the technical features of both DC devices are compared in Section 5), both devices are able to 
reach roughly the same maximum acceleration (about 600-700 × g) and have about the same 
ratio between the main and secondary rotation (about 3-4:1), which is sufficient for making 
liposomes from highly concentrated lipid dispersions.
2.2.2. Vial orientation during DC
Vials with a rather longish shape can be placed into the dual rotor in two different orienta-
tions—vertical or horizontal in relation to the plane of the second rotation unit (Figure 4). 
These different orientations result in two different homogenization processes.
2.2.2.1. Vertical vial orientation
Using the vertical vial orientation, the rotating vessel walls are always equally distant from 
the secondary rotation axis. Processing highly concentrated lipid dispersions, the viscous 
and sticky material adheres to the rotating vessel wall, whereby it is transported against the 
Figure 4. Vertical and horizontal orientation of long-shaped vials into a dual rotor.
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 centrifugal forces (inward movement). At the same time, the centrifugal force pushes the sam-
ple material that is not in close contact to the vessel wall in the opposite direction (outward 
movements). Both contrary movements results in strong friction and shear forces within the 
viscous material and thus, in homogenization (Figure 5, left). Homogenization using verti-
cal vial orientation is especially effective in vials with a rather large diameter, e.g., 150 ml 
 disposable PP beakers for the homogenization of bigger batches (Figure 5, right).
2.2.2.2. Horizontal vial orientation
Using the horizontal vial orientation, the position of the vial in relation to the centrifugal 
acceleration changes continuously while turning around the second axis (Figure 6). Having 
the lengthy vial parallel to the acceleration vector allows the material to gain speed and 
kinetic energy over a rather long distance, thus clashing to the top or the bottom of the vial 
with high impact. Within the next forth of rotation, nothing happens until the vial turns into 
an angel, which allows the movement of the sample material again. “From the vials point of 
view,” the sample material constantly moves from the bottom to the top of the vial with high 
acceleration, including a soft transition in between. This type of movement is similar to that in 
a horizontal ball mill, with the difference that the acceleration of the sample material (and the 
balls) in DC is much higher and always constant (up to 1.000 × g). Especially when very small 
amounts of sample material will be homogenized in small vials (e.g., PCR tubes or 2 ml PP 
vials), the horizontal orientation is much more effective than the vertical orientation.
2.2.3. Homogenization aids
Despite liposome preparation by DC-homogenization is possible without any homogeniza-
tion aids, the outcome gets better and the process faster if homogenization aids, in the form 
of heavy beads, are added. Those beads work in two ways: on the one side, the beads help to 
bring the sticky and viscous lipid blends rapidly in motion—simply by increasing the  density 
Figure 5. Left: Schematic view into a rotating vial in a dual rotor. At the same time, the viscous sample material (e.g., 
VPGs)—is transported against the centrifugal forces due to adhesion to the vessel wall, and in the opposite direction 
due to centrifugal acceleration of sample material rather distant to the vessel wall. Both contradictory movements result 
in shear forces and inner friction of the viscous sample material and thus, homogenization and formation of small 
liposomes. Right: Using standard PP beakers in a dual centrifuge placed in vertical orientation (view from top).
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of the  bead-lipid-water mixture and thus its potential energy which is not only a function 
of the centrifugal force but also of the weight of the accelerating material. On the other side, 
DC-homogenization is more effective due to the collision between the beads—with the viscous 
lipid mixture in between. That the bead-bead interactions play an important role for effective 
homogenization is supported by the finding that an increase in the number of beads while keep-
ing the bead mass constant (smaller beads) results in the best DC-homogenization (more beads—
more bead-bead interactions). Possible bead materials are glass, stainless steel, or ceramic.
2.2.3.1. Glass beads
At the onset of the development of DC-homogenization, glass beads which are cheap, easy 
to sterilize, and believed to be inert have been used. However, it turned out that glass beads 
get rapidly smaller during DC, which can be explained by their rather soft surface and the 
very frequent bead-bead interactions. In addition, depending on the intensity of the DC pro-
cess and the processing time, samples developed an unpleasant smell of fish, a phenomenon 
which unfortunately was reproducible. We concluded that the frequent interactions between 
the glass beads results in micro- and nano-sized glass particles (dust) with a huge and, of 
course, fresh basic surface, e.g., due to the potassium oxide within the glass. We propose that 
due to these polar and basic particles, a so-called Hoffmann elimination of phosphatidylcho-
lines takes place (Figure 7), resulting in phosphatidic acid, acetaldehyde, and trimethylamine, 
explaining the fishy smell. The reaction proposed here belongs to the field of heterogenic 
catalysis and has not been seen so far with phospholipids. Beside chemically of interest, even 
a little degradation of phospholipids due to the use of glass beads might be a problem. Thus, 
after a few initial studies, we completely avoided glass beads in DC for making liposomes.
Figure 6. Schematic view into a lengthy vial in a dual rotor in “horizontal orientation,” showing the movement of sample 
material (for detailed description of the process, see text). Below and left: Adapter for placing 20 × 2 ml vials in a dual 
centrifuge in horizontal position (only one of the two possible adapters is shown).
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2.2.3.2. Stainless steel beads
The biggest advantage of steel is its high density of typically > 7.5 kg/l, which would be ideal 
to support the process of the “in-vial” homogenization. Unfortunately, steel has a rather soft 
surface, resulting in steel abrasion that is not acceptable for formulations used in cell culture, 
animal experiments, or in men. Generation of lipophilic steel abrasion can easily be seen by 
the resulting yellowish-colored liposome preparations.
2.2.3.3. Ceramic beads
Ceramic is the material of choice, and there is a lot of experience for beads made of zircon 
oxide stabilized with yttrium (ZY-beads). ZY-beads have a density of > 6 kg/l, which is 
about three times higher than glass. In contrast to glass and steel, the surface is extremely 
hard (microhardness: 1.200 HV [hardness according to Vickers, corresponding to a Mohrs-
hardness between 7 and 8]). ZY-beads are commercially available, even in food and pharmacy 
grade. Finally, using ZY-beads resulted in the best DC-homogenization so far (unpublished 
data). A typical procedure for making liposomes is to add the same weight of beads, as the 
weight of the lipid-water mixture in the respective vial. A typical diameter of ZY-beads used 
for liposome preparation is 1.5 mm which is big enough to subsequently remove the beads by 
filtration, or—after dispersion of the resulting VPG—by simply removing the liquid disper-
sion by a standard pipette, the beads are too big to be sucked into the pipette.
It has to be mentioned that zirconia-containing particles are in use to remove traces of phos-
pholipids from extracts of biological samples to reduce the matrix effects during MS-analytics. 
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Figure 7. Proposed mechanism of the degradation of phosphatidylcholine during DC of phospholipid blends with glass 
beads as homogenization aids (top: Overview of the Hoffmann elimination of phosphatidylcholine. Below: Mechanism 
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Thus, it can be assumed that the ZY-beads used for DC-homogenization also interact with the 
phospholipids during VPG production, an effect—if real—which obviously has no negative 
effect on liposome production.
3. Potential of the DC-liposome technique
Manufacturing of liposomal dispersions destined for human use and biomedical research 
should fulfill some important criteria, and the resulting liposomes should (i) be uniform/
homogeneous, (ii) have a reproducible particle size range, (iii) be sterile, and (iv) be free of 
any traces of harmful substances such as organic solvents or glass residues. Not related to the 
manufacturing process, but very helpful for its acceptance would be an adequate shelf life of 
the liposomes [1]. In addition, the cost- and time-effectiveness of the manufacturing process 
should be considered. Based on these criteria, we discuss the potential of the newly developed 
DC-homogenization in liposome production in relation to
I. its reproducibility and robustness (Section 3.1),
II. the possible batch sizes and the sample capacity (Section 3.2),
III. the gentleness of the DC method as compared to other liposome preparation methods 
(Section 3.3) and
IV. the cost-effectiveness relative to other methods (Section 3.4)
In addition to these issues, we also discuss the potential of applying DC for the dilution of 
VPGs to normal liposomal dispersions (Section 3.5).
3.1. Reproducibility and robustness of the DC method (liposome size, PI, and EE)
3.1.1. Lipid concentration and composition
As already stated in Section 2, efficient homogenization and size reduction by DC demand 
concentrated and thus viscous lipid dispersions. With increasing lipid concentrations from 
10% (w/v) up to 35% (w/v), an improved efficiency of DC-homogenization was observed, 
which was illustrated by decreasing vesicle sizes [15]. The reproducibility of the process was 
also improved with higher lipid contents, resulting in a lower variability of the liposome sizes 
between the batches. However, there is a threshold lipid concentration, and VPGs made from 
50% (w/v) lipids showed a small increase in size and a poorer reproducibility [15]. Thus, a 
lipid concentration range between 35 and 45% (w/v) seemed advisable regarding the applied 
DC processing conditions; EPC3/cholesterol (55:45 mole/mole; 0.5 g batches in 30 ml injection 
vials plus 0.5 g glass beads (Ø = 1 mm); DC for 30 minutes at 3540 rpm (Speedmixer DAC 150 
FVZ). However, different threshold values have been reported with different lipids applied. 
When a phospholipid mix with 80% phosphatidylcholine (Lipoid E-80) was the applied lipid 
raw material, VPGs with up to 50% lipids were successfully prepared [26]. Here, the 50% 
(w/v) VPGs enabled smaller liposomes (163.4 ± 58.2 nm) with lower standard deviation and 
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batch-to-batch variations, as compared to VPGs containing less lipids (30% (w/v): 486.2 ± 92.8 
nm; 40% (w/v): 216.5 ± 76.3 nm). In addition, the more concentrated VPGs gave higher EE 
values and a lower polydispersity index (PI), with a PI of 0.287 ± 0.065 and 0.186 ± 0.044, in the 
30 and the 50% (w/v) VPGs, respectively [26].
The effect of lipid composition on the liposome size has also been demonstrated for VPGs 
with the same lipid concentration and processing conditions. Using a more rigid lipid blend 
containing saturated phosphatidylcholine (HSPC/CHOL/DSPE-PEG) resulted in bigger lipo-
somes than a more fluid mixture containing an unsaturated phosphatidylcholine (POPC/
DDAB/DSPE-PEG) in 35% (w/v) VPGs [10]. Similarly, the morphology of the liposome ves-
icles was affected by the lipid composition, with more lamellas formed in more rigid lipid 
formulations [10]. The same effect was observed when propylene glycol was added to the 
lipid  mixtures (PG-Lip) [18]. PG obviously reduces the lipid interactions in the lipid bilay-
ers and makes the membranes more flexible than the conventional liposome formulation 
without PG (C-Lip). This gave a significant shorter DC processing time required to reach the 
aimed liposome sizes of 200–300 nm, the optimal liposome size for topical drug deposition 
[27], with a processing time of 3 minutes with PG vs. 50 minutes without PG [18]. In these 
experiments, the standard deviation of the vesicle sizes, and the PI values were higher for the 
PG-Lip formulation because of the reduced processing time. However, the reproducibility of 
the processing method was still found acceptable; PI = 0.31 ± 0.03 (PG-Lip) and PI = 0.13 ± 0.02 
(C-Lip), mean liposome sizes and standard deviation (n ≥ 3) = 278 ± 66 nm (PG-Lip) and 282 ± 
30 nm (C-Lip), respectively [19].
3.1.2. Processing time
As expected, but only up to a certain extent, the DC processing time affects the vesicle size 
[15]. When using a rather rigid lipid blend consisting of saturated phosphatidylcholine and 
cholesterol (55:45 [mole/mole]), 5 minutes of DC-homogenization at maximum speed gave a 
mean liposome size of 105 nm (measured by PCS, number weighted), and after 30 minutes 
of DC processing, the size was further reduced to 62 nm with a reduced standard deviation. 
Since longer DC processing (up to 60 minutes) gave no further size reduction, a processing 
time of 30 minutes was recommended as optimal [15].
3.1.3. Mixing aids
In the first DC-experiments, the addition of glass beads as a mixing aid has been demon-
strated to increase the efficiency of the particle size reduction by DC-homogenization [15]. 
Regarding the amount of glass beads (Ø = 1 mm), the addition of 50–100% (w/w), relative 
to the total weight of the VPG, enabled the most efficient particle size reduction, as well as a 
more homogeneous size distribution [15].
Recently, alternative materials to glass as mixing aids have been tested and found more 
 appropriate (see also Section 2.2.3). Even if glass beads have been the most applied mixing aid 
in DC [10, 15–19, 21, 28–32], and the minor amounts of glass particles found in the  preparation 
postprocessing was judged acceptable [15]; new findings reported in Section 2.2.3 show that 
even a small amount of glass abrasion will catalyze the degradation of PC. Thus, ceramic beads 
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made of zircon oxide stabilized with yttrium (ZY-beads) seem to be the material of choice. 
The higher density of the ZY-beads, as compared to glass beads, results in a smaller volume 
of ZY-beads necessary to support DC-homogenization. In addition, since the ZY-beads are 
heavier and available in very small diameters, the number of beads can be increased to gain the 
aimed bead-bead interactions needed for efficient size reduction, whereas keeping the bead 
volume constant. However, successful preparation of liposomes by DC was also demonstrated 
without any mixing aid present [13, 33, 34].
3.1.4. Drug entrapment efficiency
In general, entrapping water-soluble drugs into VPGs does not seem to affect the liposome 
vesicle sizes [10, 15, 18]. The water-soluble fluorescence dye calcein has been used in several 
studies to investigate the entrapment efficiency of water-soluble drugs into DC-manufactured 
liposomes [15, 16, 21]. These studies, as well as a study where the fluorescence dye 5,6-car-
boxyfluorescein (CF) was used [35], demonstrate that the DC-VPGs enable a high EE of hydro-
philic drugs compared to what is achievable with other techniques, and typically > 50% EE is 
reported. From the previous experience with VPGs made by HPH [36], the high EE of water-
soluble drugs in the VPGs made by DC is somewhat expected. However, EE of calcein into 
VPGs made by HPH was surprisingly lower than into VPGs made by DC-homogenization 
(56.0 ± 3.3% vs. 36.0 ± 3.2%) [15]. This difference might be explained by the bigger size of the 
liposomes produced by DC (60 ± 5 nm [DC] vs. 36 ± 4 nm [HPH], both number weighted), and 
the suggested advantages of having liposomes with higher number of lipid lamellar bilayers 
(see Section 2.1.). Also in accordance with the suggestions made in Section 2.1, a higher drug 
entrapment of water-soluble drugs with increased lipid content has been demonstrated in 
several studies. As an example, EE values for the anticancer drug cytarabin (Ara-C) were 31.7 
± 0.31% in 30% (w/v) VPGs and 72.1 ± 0.25% in 50% (w/v) VPGs, respectively [6].
Also more lipophilic drugs, such as chloramphenicol (CAM), have been entrapped into lipo-
somes by DC-homogenization and EE values close to 50% were found [18, 19]. When compar-
ing this value with EE values obtained with the conventional liposome production techniques, 
probe sonication and filter extrusion, when using the same lipids and CAM-to-lipid ratio, a 70% 
increase in EE was achieved by using DC, even though the resulting liposomes were smaller 
(282 ± 30 nm) compared to those getting from sonication (836 nm) or extrusion (667 nm). Thus, 
the higher EE values were suggested to be due to the increased lipid concentration and the less 
available aqueous media for the drug to diffuse into, as CAM will be in an equilibrium between 
the dissolved portion of the drug present in the aqueous phase and the portion located in the 
lipid bilayer [18]. This is in agreement with the previous suggestions, claiming that VPGs that 
contain drugs that tend to diffuse through and from the liposome bilayers into the aqueous 
phase of the liposomal dispersion must be stored as VPGs to achieve an acceptable shelf life. 
This is because liposomal dispersions are characterized by a huge extravesicular water phase 
where these drugs will participate, and thus the EE of the drug will be reduced as soon as the 
VPGs are diluted into liposome dispersions [36].
To summarize, the most important factors affecting the size distribution for liposomes made 
by DC-homogenization are processing time, type, and size of the mixing aid, lipid concen-
tration, and lipid composition. The polydispersity index (PI) obtained for liposomes made 
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by DC is rather low compared to that of HPH, reflecting a homogeneous size distribution, 
and PI values <0.2 are frequently reported [19–21, 28, 30, 35]. However, PI increases when 
bigger liposomes are obtained due to the formulation and/or processing conditions selected 
[15, 18, 26]. Regarding the entrapping efficiency of drugs into liposomes, DC seems to be 
advantageous over other manufacturing techniques, independently of the charge or solu-
bility characteristics of the drug, and the DC method turned out to be robust and highly 
reproducible.
3.2. Batch sizes/sample capacity in DC
The batch sizes processed by DC homogenization depend on the capacity of the DC instru-
ment used. So far, the DC technology in liposome production has been demonstrated at the 
laboratory scale, and the development of this technology for industrial scale production of 
liposomes remains to be confirmed. However, some progress has been made lately, with the 
new DC prototype ZentriMix 380 R that has a higher capacity compared to the Speedmixer 
DAC 150 FVZ which has been used for the basic developments of DC-homogenization (com-
pared in Section 5 of this chapter). With the new ZentriMix 380 R, the maximum cargo has 
been substantially increased from 150 to 1000 g, but maybe more important, the number of the 
typically used 2 ml vials has been increased from 4 to 40.
The possibility of processing up to 40 samples with different compositions in the same run 
is a big advantage when conducting screening experiments, e.g., for comparing different 
liposome formulations. But also when using bigger vials, e.g., 10 ml injection vials for pre-
paring liposomes for potential human use, 10 vials can be prepared in parallel (see Table 1, 
Section 5).
Beside the advantages of DC processing of many small sample vials in one run, the possibility 
to prepare very small batches significantly helps to save costs, e.g., when doing experiments 
with expensive materials such as siRNA [10, 16], or when compounds to be entrapped or spe-
cial lipids are only available in small amounts [35, 37]. Thus, the typical batch sizes applied 
in the DC-homogenization are usually < 500 mg (2 ml vials), and batch sizes down to 20 mg 
[16] and 1–5 mg [37] have been reported as well. These small batch sizes significantly differ 
from the minimal batch sizes when using HPH. Even with one of the smallest HPH devices, 
the APV Micron Lab 40 lab-scale homogenizer, relatively huge amounts of lipids and drugs 
were necessary. Producing a VPG with a final lipid concentration of 40% would demand 16 g 
lipids and 24 g buffer to fill the 40 ml homogenization vessel [38]. Thus, with the sample mate-
rial for one HPH experiment, 400 DC experiments (á 100 mg) can be performed, which allows 
efficient screening of the optimal conditions.
However, one can discuss that small batch sizes will reduce EE values for water-soluble com-
pounds since such an effect was observed when siRNA was entrapped in conventional lipo-
somes. Reduction of the batch size from 60 to 20 mg VPG resulted in a reduction of siRNA 
entrapment from 71 to 55% [16]. The same effect was observed for siRNA in sterically stabi-
lized liposomes. Since it is known that nucleic acids have an affinity to polar glass surfaces, 
this batch size effect was explained by a possible unspecific binding of the siRNA to the vials 
surface [16]. Therefore, absorption of active ingredients onto the vial surface or to the surface 
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of the mixing aids (glass beads) might reduce EE values, especially when very small batches 
are processed. However, in the same study, entrapment of calcein, which has virtually no 
affinity to polar glass surfaces, was found not to be affected by the samples size [16].
Small batch sizes are also advantages when toxic materials, such as cytostatic or radioac-
tive compounds, are used as ingredients in liposomes formulation. Since the DC method 
also facilitates handling samples in the closed container, it is advantageous to the environ-
mental and personnel safety concerns. Thus, DC was the method of choice and enabled 
successful preparation of Ara-C containing VPGs for a local injection into the brain tissue, 
to provide a sustained drug release in treatment of gliomas, and in vivo studies in rat and 
mice models [26].
3.3. Gentleness of the DC method and advantages of closed container in DC
3.3.1. Temperature
All homogenization methods suitable for liposome size reduction are based on bring-
ing energy into the sample through applying shear forces, which also contribute to a 
temperature increase of the sample. Rise in temperature will accelerate any hydrolytic 
degradation processes and should be avoided to protect phospholipids and other con-
stituents from degradation. Since the Speedmixer DAC 150 FVZ has no cooling unit, the 
temperature and gentleness of the processing method were investigated carefully [15]. 
For comparison, VPGs were also prepared by the HPH performing 10 homogenization 
cycles at 700 bars. Both, DC- and HPH-liposomes were analyzed for phospholipid hydro-
lysis by measuring the content of the hydrolysis product, lyso-phosphatidylcholine (lyso-
PC). The results showed that there was only a slight increase in lyso-PC during the DC 
processing (<0.1%), whereas the liposomes processed by HPH had a lyso-PC increase 
of approximately 1% when autoclaved, which is necessary to get sterile formulations 
[15]. The temperature of the sample during the DC was also monitored and found not 
to exceed 50 ± 1°C during the 30 minutes processing time (6 × 5 minutes, interrupted by 
mandatory breaks for downcooling) [15].
When 40% (w/w) DC-VPGs, containing Ara-C and added sodium sulfite as a preservative, 
were autoclaved, no chemical degradation was noticed after autoclaving, as no degradation 
products neither for the Ara-C drug nor for the E80 lipids applied in the formulation were 
found. The only change observed was an improved viscosity [26]. These results are in accor-
dance with the earlier studies on autoclaving of VPGs made by HPH that was also proven 
stable during autoclaving [39].
The gentleness of the DC method opens new applications for VPGs and liposomes, namely, to 
incorporate highly sensitive drugs such as proteins, i.e., References [13, 28, 34]. As regards to 
the lack of a cooling unit, the short-run cycles are a common way to control the temperature 
rise, and Tian et al. [13] made 1.5 minutes of centrifugation steps interrupted by a cooling at 
2–8°C every 6–8 runs, which gave a successful incorporation of model protein erythropoietin 
(EPO) into the VPGs. However, the new DC device ZentriMix 380 R is equipped with a pow-
erful cooling unit, which allows also longer runtimes without cooling down breaks.
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3.3.2. Closed container
Since DC homogenization is carried out in closed container(s), the sample vial(s) can be flushed 
with inert gas to reduce oxidation of sensitive components. This is however not the normal 
praxis, but sealing of the vials under nitrogen prior to autoclaving of VPGs has been reported 
[26]. Others have stored DC vials prefilled with beads and lipids (lipid film) under argon at RT 
until use [17]. The concept of making a homogeneous lipid film (molecular dispersed lipid mix-
ture) directly in the DC vials for subsequent hydration and DC-homogenization has been dem-
onstrated and found highly useful to optimize the “in-vial” performance of the method, avoiding 
material transfer and possible material loss [18, 19]. This is contrary to other liposome processing 
methods such as the HPH, membrane extrusion, or sonication. The high material recovery has 
been demonstrated by phosphorous determination in the liposomes after DC-homogenization 
and removal of the nonentrapped drug by filtration and or/or dialysis [19]. These results show 
a lipid recovery of about 100% after the DC-homogenization, and a lipid loss of approximately 
13% after dialysis and filtration (0.22 μm filter). Thus, if acceptable EE values are obtained and a 
removal of nonentrapped drug is avoided, a close to 100% recovery is achievable.
The protection of light-sensitive drugs from light during liposome preparation is also possible 
by DC. In addition to the dark conditions provided in the locked DC machine, brown injection 
vials have been applied for extra protection during handling [15, 16, 18]. For comparison, when 
liposomes are prepared by the HPH, open handling is necessary to move the sample content 
from the receiver reservoir to the feeding reservoir in between every homogenization cycles 
(typically 10 cycles). Thus, to protect the sample from light during the processing, one would 
have to operate the instrument in the dark. Closed containers are also of advantage when toxic 
materials, such as cytostatic or radioactive compounds, are used as ingredients in liposomes 
formulation (environmental and personnel safety).
3.3.3. Bedside preparation
Since liposomal formulations contain water and since most low molecular weight drug molecules 
(e.g., conventional cytostatics) are able to diffuse through liposomal membranes from one aque-
ous compartment into the other, the liposome shelf life is limited to hours, days, or sometimes 
weeks. Furthermore, drug molecules sensitive to hydrolysis, like alkylants, might also hamper 
stability. Some drug molecules are also shown to promote phospholipid hydrolysis, like gem-
citabine [40] and camptothecin [41]. Taken together, shelf life is a major problem when developing 
liposomal formulations. Since DC-homogenization allows fast and straightforward preparation 
of liposomes in sterile containers, bedside liposome preparations for patient treatments might be 
one potential application of DC in the future [15]. Applying readymade kits—containing the dry 
lipid mixture, the drug molecule, and mixing aid— would make the liposome preparation easy, 
as only adding the aqueous media before the subsequent DC processing to form VPGs, remains. 
This strategy might facilitate personalized medicine and bedside preparation to take place with-
out any need for dedicated production rooms, as the DC method is performed with locked con-
tainers. Subsequent dilution (dispersion) of the VPGs and dosing of the resulting liposomes into 
an infusion bag would be one potential way of administering the drug, where the rapid infusion 
into the patient would complete the bedside preparations process. DC instruments are bench-top 
Liposomes18
machines, which fit into any hospital pharmacy, where the bedside preparation and the subse-
quent dosing can be performed. However, not only liposomes with a limited shelf life can be 
made assessable for the patients, also liposomal formulations carrying short living isotopes, e.g., 
PET tracers—for a better tumor visualization due to an improved tumor accumulation of the 
liposomes due to the EPR effect—might be a promising application for DC-homogenization. If 
necessary, the DC instruments are small enough to be placed into a sterile bench [15].
3.4. Cost-effectiveness of the DC-liposome technique
3.4.1. Easy and fast DC-homogenization
Many of the already mentioned advantages of the DC in liposome processing, such as high mate-
rial recovery [19], small sample sizes [35], and straightforward and fast procedure [19], will also 
save material cost and personnel expenses in the laboratory. As compared to the more time-con-
suming techniques such as the filter extrusion [42], HPH homogenization [36], and ultrasound 
[43], the relatively higher drug EE obtained with concentrated lipid dispersions (VPGs) may 
make the time-consuming separation step, removing nonentrapped drug from the liposome 
drug carrier, unnecessary before the administration [18]. Especially when drugs are entrapped 
into liposomes to be protected from degradation in the blood stream, one might argue that the 
resulting liposome dispersions with high entrapment might be administered without removing 
the nonentrapped drug, as the free drug will be destroyed immediately after administration into 
the blood stream [11]. An example is liposomal gemcitabine, where the free gemcitabine has a 
half-life of 9 minutes, while the liposomal gemcitabine has a half-life of 13 hours [40].
3.4.2. Device cleaning
It is not only the fast homogenization procedure that is saving time to the operator as com-
pared to other liposome techniques. With disposable and closed containers, the cleaning of 
the machine is avoided. This eliminates also the risk of cross contamination, which might hap-
pen during other methods resulting from a nonsufficient cleaning of the instrument (i.e., the 
probe applied in probe sonication—and instrumentation applied during extrusion—or HPH).
3.5. Mixing of liposomes into secondary vehicles
As DC is not only an “in-vial” homogenization tool but also an “in-vial” mixing or dispersion 
tool, DC machines are also suitable for dispersing the highly concentrated VPGs to normal 
liposomal dispersions. VPGs-dispersion in an aqueous media like a buffer can easily be per-
formed by simply adding the required volumes of aqueous media to the VPGs, using the 
same vials already used for DC-homogenization, and continuing the DC process for typically 
1–5 minutes [17, 28].
However, if topical liposome administration is the target application, there might be a need 
to disperse liposomes into more semisolid, viscous vehicles, such as hydrogels, to gain the 
wanted qualities of the product, such as texture, stability, drug release profile, and  bioadhesion 
[44–47]. The DC technique has been proven suitable for both liposome processing and further 
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mixing of the liposomes into hydrogels, and the topical preparations as liposome-in-hydro-
gels was reported to be homogeneous after DC for 5 minutes at 3500 rpm in the Speedmixer 
[18]. The DC technique has also been applied to prepare liposomes for further embedding into 
gelatin [21]. Here, the DC technique was useful for both the size reduction of the liposomes 
forming VPGs and for the direct dispersion of liposomes into gelatin. Solid matrix liposomes 
in gels are obtained from the gelatin-VPG mass after the cooling [21].
4. Dual centrifugation: current application in liposome research
Since DC-homogenization was first introduced as an innovative method for liposome prepa-
ration in 2008 [15], a number of publications have appeared reporting on this technology for 
different liposome applications. However, the most appreciated advantages of the method 
seem to be its gentleness, the unusual high EE values for water-soluble drug molecules, and 
the small batch sizes. Moreover, the majority of the publications concern the entrapment of 
heat labile peptides and proteins. These proteins and peptides have been entrapped into 
VPGs and liposomes for different routes of administration: oral [21, 30, 31], nasal [33], and 
iv injection [17, 20, 28, 29], or as VPG-depot formulations [13, 34, 48]. Various organs were 
targeted as therapeutic sites: cancerous tissue [10, 26, 35], the central nervous system (CNS) 
and brain [28, 32, 33], liver [31], and skin [18, 19].
The DC “in-vial” liposome technique has facilitated a straight forward preparation 
method for entrapment of siRNA under sterile and RNase-free conditions, with EE close 
to 50% EE [16, 49]. Targeting of the siRNA-liposomes to neuroblastoma cells through 
applying DC in a combination with a sterol-based postinsertion technique was demon-
strated in vitro [10].
Recently, the antitumor effect of anticancer drug cytarabin (Ara-C) loaded into VPGs was evalu-
ated in vivo in nude mice bearing U87-MG glioma cells, as compared to empty VPGs and free drug 
in solution. The formulations were injected subcutaneously around the tumor. For the same Ara-C-
VPG formulation, the in vivo drug release was studied in rat plasma and the in vivo biodistribution 
in rat brain evaluated for 28 days using the UPLC-ESI-MS/MS quantification assay [26]. Here, a 
sustained release of Ara-C from the VPGs was confirmed as the drug (Ara-C) administered as free 
drug in solution could be detected in rat plasma already after 7 hours postinjection into the brain, 
whereas no drug was detected after 7 days from the Ara-C-VPG formulation. Moreover, the thera-
peutic effect lasted at least for 28 days for the Ara-C loaded VPGs, and VPGs were thus suggested 
as a promising local delivery system for postsurgical sustained chemotherapy of gliomas [26].
The DC liposome technique has also been applied to explore new polymeric amphiphiles, so-
called polyether lipids or polymer-lipid conjugates, for obtaining multifunctional liposomes. 
Here, DC was offering the benefit of testing the rationally designed polymer architectures in 
a microscale [35, 50].
In a different study, a simple and reproducible method for preparing immune-magneto-liposomes 
(ML-liposomes), with iron oxide particles (SPIOS) was developed applying the DC liposome 
 “in-vial” technique. After the liposomes were formed, antigen binding to the surface of the 
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liposomes was successfully carried out applying a postinsertion technique [17]. The antigen 
should facilitate targeting of the activated platelets in atherothrombosis, and thus form a 
contrast agent for timely detection and diagnosis [17].
The DC technique has also been proven useful in preparing so-called liposomes-in-hydrogel 
formulations intended for topical application for local deposition of active ingredients and for 
a sustained release into the skin [18, 19]. In this production procedure, not only the homog-
enization and size reduction of the liposomes but also the mixing of the liposomes into the 
hydrogel vehicle was facilitated by the DC [18].
5. Description and comparison of the dual centrifuges used for liposome 
preparation
Until now, two different DC devices have been used for liposome production (compared 
in Table 1 and Figure 8). The process of DC-homogenization was first discovered using the 
Speedmixer DAC 150 ZentriMix 380 R
Number of rotation units 1 2
Diameter of the rotation unit/usable area of the 
rotation unit
7.5 cm/44 cm2 14.7 cm/170 cm2
Distance between turning-point rotor and turning-
point rotation unit
4.5 cm 10.0 cm
Primary rotation (minimum−maximum) 300–3450 rpm 50–2500 rpm
Ratio of primary and secondary rotation ~4:1 ~3:1
Maximum centrifugal acceleration at the turning 
point of the rotation unit
600 × g 700 × g
Time to maximum speed (empty) ca. 5 seconds ca. 1 minutes
Maximum cargo (sample plus adapter) 150 g 1000 g (2 × 500 g)
Cooling unit (temperature range) Nonexistent Yes (−20 to 40°C)
Runtime 5 seconds–5 minutes 1 minutes–99 hours (30 
minutes recommended)
Dimension (width × depth × height; weight); d 27.5 × 49.5 × 41.0 cm; 25 kg 47.0 × 76.0 × 40.0 cm; 82 kg
Maximum number of samples
Twist top vials, 2 ml 4 40
Injection vials, 10 ml 1 10
Beakers, 150 ml 1 2
Centrifuge tubes, 15 or 50 ml 0* 6
*Tubes are too long for the diameter of the rotation unit.
Table 1. Properties of the dual centrifuges already used for liposome preparation.
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Speedmixer DAC 150 FVZ (Hauschild GmbH & Co KG, Hamm, Germany), which was pre-
dominantly constructed for the effective mixing of two-component dental filling materials as 
well as for other mixing tasks, e.g., in the field of printing inks. To better meet the requirements 
of DC-homogenization for the production of liposomes—which in particular are longer pro-
cessing times and the need for efficient temperature control—a new dual centrifuge has been 
developed, the ZentriMix 380 R (Andreas Hettich GmbH & Co KG, Tuttlingen, Germany).
5.1. Speedmixer DAC 150 FVZ
The Speedmixer is a so-called “dual asymmetric centrifuge” (DAC), meaning that the dual 
rotor is asymmetrically built and carries only one rotation unit. The resulting imbalance dur-
ing operation is compensated by a fix or by variable counter weights. Thus, the allowed total 
cargo is fixed at 5–150 g in predefined steps. In earlier versions of the Speedmixer, for each 
different sample type a special sample vial adapter had to be used which own weight plus the 
sample weight has to be 100–150 g. This type of construction is of advantage if the number of 
samples to be processed is only one. The diameter of the vial holder is approximately 7 cm 
which limits the number of 2 ml vials that can be processed in parallel to 4. Typical lab PP 
beakers with a volume of 150 ml can be processed easily, but not vials longer than 7 cm (e.g., 
15 or 50 ml disposable centrifuge tubes).
Due to its powerful engine and the rather low weight of the dual rotor, the Speedmixer needs 
only seconds to reach its maximum speed. The second rotation for the DC process and the 
Figure 8. Pictures of the two dual centrifuges: the Speedmixer DAC 150 FVZ (left) and the ZentriMix 380 R (right). Their 
respective rotors with typical vial holders are shown in the small pictures.
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main rotation are mechanically couplet by a v-belt, which has advantages in compensating 
the forces during acceleration, but also contributes to the rapid contamination of the rotor unit 
with rubbed-off parts of the v-belt.
The Speedmixer is constructed for rather short runs, and the effective mixing of the mentioned 
dental filling materials needs only 15 seconds. Longer runtimes resulted in a significant and 
rapid development of heat caused by the powerful engine and the used mechanic elements 
(v-belt mechanics and the bearings are deeply embedded in the rotor case). Since the heat pro-
duction is intense, and no cooling unit is implemented, the maximum allowed and adjustable 
runtime is 5 minutes. Thus, reaching a runtime of 20–30 minutes needed for making liposomes 
by DC-homogenization, the Speedmixer has to be restarted at least 4–6 times. If temperature-
sensitive samples have to be processed, it is necessary to patiently allow the Speedmixer as well 
as the samples to cool down between the 5-minute runs. For very sensitive samples, shorter runs 
have to be performed allowing intermediate downcooling of the Speedmixer and—more impor-
tant—the samples. Running the Speedmixer in a cool place (cooling chamber) is of advantage.
5.2. ZentriMix 380 R
To improve the in-vial homogenization process in terms of temperature control, longer process-
ing times and flexibility in the number, shape, and size of the sample vials, a new type of dual 
centrifuge (ZentriMix 380 R) was developed. In contrast to the Speedmixer, the ZentriMix is a 
symmetric dual centrifuge, meaning that the dual rotor carries two symmetrically placed rota-
tion units. However, the abbreviation of this type of dual centrifugation is simply DC, but one 
might discuss if DSC would be more appropriate—as the opposite of the abbreviation DAC.
The dual rotor of the ZentriMix is rather heavy (≈15 kg), very robust, and can process cargos 
from a few milligrams up to 1 kg (2 × 500 g). Due to its higher weight, acceleration of the 
ZentriMix rotor is comparable to that of a normal centrifuge.
The ZentriMix is superior for long runtimes, the technical limit being 99 hours. This was not 
only achieved through the robust rotor case but also by a very robust mechanical coupling 
between the rotation units and the main rotation. This coupling has been realized through 
cogwheels made of polyamide, which also keeps the operation noise in an acceptable range. 
Furthermore, accumulation of heat is almost entirely prevented by a powerful cooling unit. For 
an optimal heat transport, sample vial holders made of aluminum are available (sample vial 
holders are usually made of polyamide), which further helps to keep the sample temperatures 
in acceptable ranges for most applications, even when 40 samples were processed at once.
6. Conclusion
DC has proven to be a straightforward and reproducible method for the production of various 
types of liposomes carrying a broad variety of drugs/active compounds. The method allows the 
preparation of different batch sizes. Especially interesting is the possibility to produce sterile 
liposomes; it is attractive for the immediate preparation of liposomes for in vitro cell culture or 
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in vivo animal experiments. The new dual centrifuges with improved manufacturing features 
and ability to control the in-vial homogenization process (e.g., by temperature control) will 
further contribute to the success of DC in the field of liposome preparation.
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